Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 2 | 2 |
1.1 List of Tables | 3 | 1 |
1.2 List of Figures | 3 | 1 |
2 Executive Summary | 4 | 1 |
2.1 Unmet Needs Remain in COPD Market | 4 | 1 |
2.2 First-in-Class Innovation Beginning to Emerge in COPD | 4 | 1 |
2.3 COPD Lags Behind Asthma in First-in-Class Innovation | 4 | 1 |
3 The Case for Innovation in COPD | 5 | 4 |
3.1 Growing Number of Opportunities for Biologic Products | 6 | 1 |
3.2 Diversification of Molecular Targets | 6 | 1 |
3.3 Innovative First-in-Class Product Developments Remain Attractive | 6 | 1 |
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation | 7 | 1 |
3.5 Sustained Innovation | 7 | 1 |
3.6 GBI Research Report Guidance | 8 | 1 |
4 Clinical and Commercial Landscape | 9 | 10 |
4.1 Disease Overview | 9 | 1 |
4.1.1 Epidemiology | 9 | 1 |
4.1.2 Symptoms | 9 | 1 |
4.1.3 Etiology | 9 | 1 |
4.1.4 Pathophysiology | 9 | 2 |
4.1.4.1 Pathophysiology of COPD in Comparison with Asthma | 11 | 1 |
4.1.5 Diagnosis | 11 | 1 |
4.1.6 Assessment of Disease Severity | 11 | 1 |
4.1.7 Treatment | 12 | 2 |
4.1.8 Treatment Algorithm | 14 | 1 |
4.2 Overview of Marketed Products | 14 | 1 |
4.2.1 Molecule Type and Target Analysis | 15 | 1 |
4.2.2 Quick Relief Medication | 15 | 1 |
4.2.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy | 15 | 1 |
4.2.4 Bronchodilator Monotherapy | 16 | 1 |
4.2.5 Bronchodilator Combination Therapy | 17 | 1 |
4.2.6 Alternative Therapy | 17 | 1 |
4.2.7 Conclusion | 17 | 1 |
4.2.8 Unmet Needs | 18 | 1 |
5 Assessment of Pipeline Product Innovation | 19 | 11 |
5.1 Molecular Target Analysis | 21 | 5 |
5.2 Comparative Distribution of Programs between COPD Market and Pipeline by Therapeutic Target Family | 26 | 1 |
5.3 First-In-Class Pipeline Programs Targeting Novel Molecular Targets | 26 | 4 |
6 Signaling Pathways, Disease Causation and Innovation Alignment | 30 | 3 |
6.1 The Complexity of Signaling Networks in COPD | 30 | 1 |
6.2 Signaling Pathways and First-in-Class Molecular Target Integration | 30 | 1 |
6.3 First-in-Class Target Matrix Assessment | 31 | 2 |
7 First-in-Class Target Evaluation | 33 | 6 |
7.1 Pipeline Programs Targeting Toll-Like Receptor 3 | 33 | 1 |
7.2 Pipeline Programs Targeting Adenosine A(2B) Receptor | 34 | 1 |
7.3 Pipeline Programs Targeting Prostaglandin D2 Receptor 2 | 34 | 1 |
7.4 Pipeline Programs Targeting P-selectin | 35 | 1 |
7.5 Pipeline Programs Targeting Macrophage Metalloelastase | 35 | 1 |
7.6 Pipeline Programs Targeting Rho Associated Protein Kinase 1 | 36 | 1 |
7.7 Pipeline Programs Targeting Soluble Epoxide Hydrolase | 37 | 1 |
7.8 Pipeline Programs Targeting Vasoactive Intestinal Peptide Receptor Family | 37 | 1 |
7.9 Conclusion | 38 | 1 |
8 Deals and Strategic Consolidations | 39 | 9 |
8.1 Industry-Wide First-in-Class Deals | 39 | 1 |
8.2 Licensing Deals | 40 | 3 |
8.3 Co-development Deals | 43 | 2 |
8.4 First-in-Class Programs not Involved in Licensing or Co-Development Deals | 45 | 3 |
9 Appendix | 48 | 6 |
9.1 References | 48 | 3 |
9.2 Abbreviations | 51 | 1 |
9.3 Research Methodology | 51 | 1 |
9.4 Secondary Research | 52 | 2 |
9.4.1 Marketed Product Heatmaps and Treatment Algorithm | 52 | 1 |
9.4.1.1 Market Analysis | 52 | 1 |
9.4.2 Pipeline Analysis | 52 | 1 |
9.4.2.1 Overall Pipeline | 52 | 1 |
9.4.2.2 First-in-Class Analysis | 52 | 1 |
9.4.3 First-in-Class Matrix Assessment | 52 | 1 |
9.4.4 First-in-Class Target Profiles | 53 | 1 |
9.4.5 Licensing and Co-Development Deals | 53 | 1 |
9.5 Contact Us | 53 | 1 |
9.6 Disclaimer | 53 | 1 |